(4-氯-3-羟基苯基)硼酸 | 915201-06-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: (4-氯-3-羟基苯基)硼酸
• 中文别名: 4-氯-3-羟基苯基硼酸
• 英文名称: (4-chloro-3-hydroxyphenyl)boronic acid
• CAS: 915201-06-8
• 化学式: C₆H₆BClO₃
• mdl: MFCD10697413
• 分子量: 172.376
• InChiKey: XMMHXKOVZNBHSA-UHFFFAOYSA-N

物化性质

• 熔点：
  >250 °C
• 沸点：
  359.9±52.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.87
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-3-hydroxyphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-3-hydroxyphenylboronic acid
CAS number: 915201-06-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6BClO3
Molecular weight: 172.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4-氯-3-羟基苯基)硼酸 在 四氧化锇 、 甲基磺酰胺 、 sodium methylate 、 palladium diacetate 、 N-甲基吗啉氧化物 作用下， 以 甲醇 、 水 、 乙腈 、 叔丁醇 为溶剂， 反应 98.75h， 生成 (2R,3S,4R,5S,6R)-2-(4-chloro-3-hydroxyphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
  参考文献：
  名称：

  [EN] MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
  [FR] DÉRIVÉS DE MANNOSE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES

  摘要：

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的公式为I：。发明还提供了包含这些化合物的药用可接受组合物，以及使用组合物治疗细菌感染的方法。最后，发明提供了制造本发明化合物的方法。

  公开号：

  WO2013134415A1
• 作为产物：
  描述：

  5-溴-2-氯苯甲醚 在 正丁基锂 、 三溴化硼 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 为溶剂， 反应 18.5h， 生成 (4-氯-3-羟基苯基)硼酸
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION

  摘要：

  本申请公开了抑制Btk的化合物、抑制ΡΒΚδ的化合物，以及既是Btk又是PI3Kδ的双重抑制剂的化合物。还描述了合成这些抑制剂的方法，以及利用这些抑制剂治疗疾病的方法，其中抑制Btk和PI3Kδ对患有该疾病的患者提供治疗益处。

  公开号：

  WO2015058084A1

文献信息

• [EN] POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES<br/>[FR] COMPOSÉS POLYCYCLIQUES ET MÉTHODES POUR LA DÉGRADATION CIBLÉE DE POLYPEPTIDES DU FIBROSARCOME RAPIDEMENT ACCÉLÉRÉ
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2020051564A1

  公开（公告）日：2020-03-12

  The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物ULM—L—PTM，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及含有一端结合到相应E3泛素连接酶的Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，另一端结合到目标蛋白RAF的部分，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。
• [EN] PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK)<br/>[FR] DÉRIVÉS PYRAZOLO-, IMIDAZOLO- ET PYRROLO-PYRIDINE OU -PYRIMIDINE UTILISÉS COMME INHIBITEURS DE LA KINASE DE BRUTON (BTK)
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2015069441A1

  公开（公告）日：2015-05-14

  The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of ΡI3Κδ, and compounds that are dual inhibitors of both Btk and PI3Kδ. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3Kδ provides a therapeutic benefit to a patient having the disease.

  本申请公开了抑制Btk的化合物、抑制ΡI3Κδ的化合物，以及同时抑制Btk和PI3Kδ的双重抑制剂化合物。还描述了合成这些抑制剂的方法，以及利用这些抑制剂治疗疾病的方法，其中抑制Btk和PI3Kδ对患有该疾病的患者提供治疗益处。
• 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
  申请人：GiraFpharma LLC

  公开号：US20190023702A1

  公开（公告）日：2019-01-24

  1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了作为腺苷受体调节剂的1,8-萘啶酮化合物。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• Highly Potent First Examples of Dual Aromatase−Steroid Sulfatase Inhibitors based on a Biphenyl Template
  作者：L. W. Lawrence Woo、Toby Jackson、Aurélien Putey、Gyles Cozier、Philip Leonard、K. Ravi Acharya、Surinder K. Chander、Atul Purohit、Michael J. Reed、Barry V. L. Potter

  DOI：10.1021/jm901705h

  日期：2010.3.11

  cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS). The aromatase inhibitory pharmacophore was thus introduced into a known biphenyl STS inhibitor to give a series of novel dual aromatase−sulfatase inhibitors (DASIs). Several compounds are good aromatase or STS inhibitors and DASI 20 (IC50: aromatase, 2.0 nM; STS, 35 nM) and its chlorinated congener

  针对多种药物靶标的单一药物的兴趣日益增加。通过双重抑制芳香化酶和类固醇硫酸酯酶（STS），可以更有效地治疗激素依赖性乳腺癌（HDBC）。因此，将芳香化酶抑制药效基团引入了已知的联苯STS抑制剂中，从而制得了一系列新型的双重芳香化酶-硫酸酯酶抑制剂（DASIs）。几种化合物是良好的芳香酶或STS抑制剂，DASI 20（IC 50：芳香酶，2.0 nM； STS，35 nM）及其氯化同源物23（IC 50：芳香酶，0.5 nM； STS，5.5 nM）是很好的双重JEG-3细胞的效力。两个联苯共用一个对位-含氨基磺酸酯的环B和环A，其在联苯桥和腈上含有三唑-1-基甲基间位。口服1 mg / kg时，20和23会强烈降低血浆雌二醇水平，并在体内有效抑制肝脏STS活性。23是非雌激素的，可有效抑制碳酸酐酶II（IC 50 86 nM）。使配合物结晶，并通过X射线晶体学解析其结构。此类DASI应鼓励HDBC向多目标治疗干预的进一步发展。
• Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine RET Inhibitors
  作者：Casey J. N. Mathison、Yang Yang、John Nelson、Zhihong Huang、Jiqing Jiang、Donatella Chianelli、Paul V. Rucker、Jason Roland、Yun Feng Xie、Robert Epple、Badry Bursulaya、Christian Lee、Mu-Yun Gao、Jennifer Shaffer、Sergio Briones、Yelena Sarkisova、Anna Galkin、Lintong Li、Nanxin Li、Chun Li、Su Hua、Shailaja Kasibhatla、Jacqueline Kinyamu-Akunda、Rie Kikkawa、Valentina Molteni、John E. Tellew

  DOI：10.1021/acsmedchemlett.1c00450

  日期：2021.12.9

  toward the discovery of small-molecule therapeutics. Hits uncovered via the analysis of archival kinase data ultimately led to the identification of a promising pyrrolo[2,3-d]pyrimidine scaffold. The optimization of this pyrrolo[2,3-d]pyrimidine core resulted in compound 1, which demonstrated potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday

  选择性抑制 RET 激酶作为相关癌症类型（包括肺腺癌）的治疗方法近年来引起了人们的极大兴趣，并促使人们为发现小分子疗法做出了各种努力。通过分析存档激酶数据发现的命中最终导致鉴定出有前途的吡咯并 [2,3- d ] 嘧啶支架。这种吡咯并 [2,3- d ] 嘧啶核心的优化产生了化合物1，其在小鼠中多日给药后在 RET 驱动的肿瘤异种移植物中表现出有效的体外 RET 激酶抑制和强大的体内功效。行政管理1在确定的有效剂量（10 和 30 mg/kg，po，qd）下耐受性良好，血浆暴露水平表明体内 KDR 或 hERG 抑制的风险最小，分别通过 Miles 测定和游离血浆浓度进行评估。